Day: April 8, 2024

The unique solution for defense applications is based on the Mars platform technology Rehovot, Israel, April 08, 2024 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a B2B provider of artificial intelligence (“AI”) accelerated video solutions for edge platforms, today announced that it has received a new order for approximately $110,000 from an existing customer in the defense industry, for a unique solution based on the technology of the Company’s Mars platform of miniature intelligent surveillance solutions that provide advanced video streaming and recording capabilities. Based on this order, Maris-Tech will develop a novel, miniaturized, low-power system with narrow-band wireless communication designed for intelligence gathering and other defense applications. The “Maris-Tech is positioned...

Brings A Unique Immersive Media Experience to the Festival Weekend MIAMI and SEOUL, South Korea, April 08, 2024 (GLOBE NEWSWIRE) — Captivision Inc. (NASDAQ: CAPT), a pioneer and exclusive manufacturer of architectural media glass, announces a partnership with Framework and a prominent entertainment and streaming service partner to bring an immersive experience to the Framework in the Desert afterparty in Coachella Valley during the upcoming festival weekend. Captivision will deliver a unique media glass installation over three nights from Friday, April 12 through Sunday, April 14. The strategic partners are creating a revolutionary experience through Captivision’s innovative media glass installed on modified freight containers. This collaboration marks the inception of a new area of strategic focus for Captivision dedicated to...

LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for poster presentation at the 2024 ATS International Conference being held May 17-22, 2024 in San Diego, CA. Details of the presentation are as follows: Title: Altered NKT Cell Populations in the Airways of Patients With IPF Poster Board Number: P1352 Presenter: Albert Agro, PhD, Chief Medical Officer of GRI Bio Session: A32: Bench to Bedside in ILD Date and Time: May 19, 2024 from 11:30-1:15 PM PT For more information about the 2024 ATS International Conference, please visit the conference website, here. About...

— Collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity — — Patient enrollment expected to be completed in 2024 — MELVILLE, N.Y., April 08, 2024 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced a collaboration with Galen Patient Recruitment, Inc. (“Galen”) which, combined with the recent expansion of clinical trial capacity from approximately 10 to 30 participants per month, is expected to help accelerate the completion of patient enrollment in the ongoing Phase 2 study of BioRestorative’s lead clinical candidate, BRTX-100, in chronic lumbar disc disease (“cLDD”). BRTX-100 is a novel cell-based therapeutic engineered to target areas...

SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial. MONTPARK (EudraCT number 2023-504278-39-00) is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD. The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm® or placebo twice daily for 18-months, followed by a 3-month washout period. Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic...

MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at the INNODIA Annual Meeting in Leuven, Belgium on April 11, 2024. SAB will be featured as a key partner at the upcoming global T1D meeting. INNODIA accelerates the development of disease modifying therapies for T1D by supporting medicine developers with the following services: teams of leading experts to advise medicine developers; a best-in-class...

New release provides insurers and reinsurers with tools to make informed decisions and mitigate potential losses effectively JERSEY CITY, N.J., April 08, 2024 (GLOBE NEWSWIRE) — Verisk, (Nasdaq: VRSK), a leading global data analytics and technology provider, has announced a monumental leap forward in global catastrophe modeling and risk analysis with the launch of Verisk’s Next Generation Models (NGM). This suite of 100+ models will be implemented by insurers and reinsurers to evaluate risk across the globe with a new financial modeling framework designed to reflect anticipated insured losses from extreme events more accurately than ever before. These advances from Verisk’s Extreme Event Solutions business are now available on Verisk’s pioneering catastrophe risk management software platform, Touchstone, which is used by...